Home / News
Baxter International Taps Medtech Veteran John Rogers as New CFO
• Baxter International appoints John Rogers, former Boston Scientific CFO, as its new Chief Financial Officer effective immediately.
• Rogers brings over 20 years of financial leadership and will oversee all global finance operations, reporting to CEO José Almeida.
• The strategic hire aims to bolster financial discipline as Baxter focuses on core units post its 2024 Vantive spin-off.
• Rogers' expertise in capital allocation and M&A is expected to drive Baxter's growth in hospital solutions and medication delivery.
Baxter International Inc., a global medtech leader, has strengthened its executive team with the appointment of John Rogers as its new Chief Financial Officer. Rogers, a seasoned financial executive with more than two decades of experience in the life sciences sector, joins Baxter from his most recent role as CFO at a major healthcare corporation. He is expected to assume responsibility for Baxter's worldwide financial operations immediately, reporting directly to Chairman, President and CEO José (Joe) Almeida.
Rogers' mandate encompasses financial planning, treasury, tax, investor relations, and internal audit. Company leadership expressed strong confidence that his proven track record in capital allocation, mergers and acquisitions, and building high-performance teams will be instrumental. "John's deep expertise in the medtech landscape and navigating complex global markets aligns perfectly with our strategic objectives," stated Almeida, underscoring the appointment as a pivotal move for Baxter's financial future and its mission to save and sustain lives.
The recruitment comes at a transformative period for the company. Following the completion of its spin-off of the renal care and acute therapies units into the independent entity Vantive in 2024, the "new Baxter" is sharpening its focus on core businesses. These include integrated hospital solutions, medication delivery, and pharmaceuticals. In this streamlined structure, Rogers' financial leadership is deemed paramount to driving growth, operational efficiency, and shareholder value.
With a significant tenure at Boston Scientific, where he held several senior financial positions, Rogers is recognized for his strategic financial discipline. His appointment signals Baxter's commitment to executing its long-term innovation and growth strategy with rigorous fiscal oversight. Stakeholders will be watching closely as Rogers shapes the financial framework intended to support Baxter's next chapter in a competitive healthcare landscape.